Surgical management of avascular necrosis of the femoral head: an update

Abstract: Osteonecrosis or avascular necrosis of the femoral head (ANFH) is a progressive, multifactorial, and disabling disease that can result in significant clinical morbidity and affect patients of any age, including young and active patients. The pathogenesis and etiology of nontraumatic ANFH has not been elucidated completely, but could be mainly due to an inadequate blood supply, causing death of osteocytes and bone marrow cells. Surgical procedures like core decompression, nonvascularized autologous bone grafts, porous tantalum implant procedures, and various osteotomies have been used to delay progression of the disease and conversion to total hip arthroplasty. Noninvasive treatment modalities like pharmacologic measures, electrical stimulation, shock wave therapy, and electromagnetic field therapy are also used to treat ANFH. Various efforts have been made in an attempt to enhance the healing of osseous defects at the femoral head before collapse occurs. Current treatment techniques for ANFH have varying results, according to the patient population and disease stage involved. With modifications of older techniques and developing technologies, treatment strategies have the ability to alter the course of ANFH. Further management options are required for the treatment of ANFH, and will be widely studied in the coming decades.

Keywords: avascular necrosis, osteonecrosis, femoral head, total hip arthroplasty, core decompression, hip

Introduction

Osteonecrosis or avascular necrosis of the femoral head (ANFH) is a progressive, multifactorial, and disabling disease that can result in significant clinical morbidity and may affect patients of any age, including young and active patients. The pathogenesis and etiology of nontraumatic ANFH has not been elucidated completely, but could be mainly due to an inadequate blood supply causing death of osteocytes and bone marrow cells.¹

Total hip arthroplasty is the most common definitive way of treating high-grade ANFH. This disorder is commonly seen in young adults, so joint-sparing therapeutic techniques have been the focus of research in the last decade. Clearly, ANFH is a challenging disorder to treat, but developments in basic science and clinical investigation will enable effective treatment options in the future.

Factors affecting treatment outcome

Radiological findings

The primary radiological findings which determine the treatment outcome are impairment of the femoral head and whether femoral head collapse and acetabular involvement
has occurred or not. The “crescent sign” observed before occurrence of femoral head collapse may indicate future mechanical failure. When hip joint surface involvement is less than 15%, this is considered to be a good prognostic factor and involvement above 30% is considered to be a bad prognostic factor.

Femoral head collapse may have two bad prognostic features, the first one of which is collapse of the femoral joint surface of more than 2 mm and the second is the presence of a collapse field wider than 30% of the total femoral joint surface.

In surgical treatment of ANFH, when deciding whether the femoral head will be preserved or not, acetabular involvement should be taken into account. Joint space preservation may also be found in cases with acetabular involvement. Sparing of the femoral head may result in treatment failure in such cases.

Intraoperative factors
In addition to preoperative investigations, intraoperative findings are also important in deciding on the correct treatment option. Intraoperative arthroscopic investigation of the hip joint is suggested to determine the condition of the joint cartilage. When arthroscopy is not available, computed tomography scanning could be helpful.

Patient-specific factors
Patient age, activity level, general health, and life expectancy are factors affecting selection of the best treatment method and its success. Range of movement in the hip joint, presence of pain, and limping should also be taken into account. Major surgical interventions should be avoided in patients with systemic disease and a short life expectancy. Therefore, similar lesions may be treated in different ways in different patients. Definitive surgical intervention, eg, total hip arthroplasty, is preferred in patients whose general health could not withstand a second procedure. Duration of preoperative symptoms is another factor that determines the success of treatment.

Nonoperative treatment
A meta-analysis in 1996 investigated the results of conventional treatment for ANFH, and observed that in 819 patients followed for 34 months without weight-bearing, more than 80% had a negative outcome. Consequently, the authors stated that the conventional approach has no place in the treatment of ANFH. Currently, conventional pharmacological and physical treatment methods continue to be used despite these negative findings. The main pharmacological agents used for treatment of ANFH are antilipidemic agents, anticoagulants, vasodilators, bisphosphonates, anabolic steroids, and prostacyclin derivatives.

Electromagnetic stimulation, extracorporeal shock wave therapy, and hyperbaric oxygen are the main physical methods used in the conventional treatment of ANFH.

Operative treatment
Conventional surgery for ANFH is divided into two groups, ie, femoral head-sparing and arthroplasty procedures. The femoral head-sparing technique is likely to have a good result if performed before femoral head collapse occurs. On the other hand, arthroplasty is preferred in cases where collapse has occurred.

Femoral head-sparing techniques
Core decompression, combined core decompression (with vascularized bone grafting and nonvascularized bone grafting), and rotational osteotomies are femoral head-sparing methods.

Core decompression
In 2000, Castro and Barrack analyzed the results of 22 studies involving application of core decompression, including eight studies involving nonoperative treatment. They concluded that the outcome of core decompression performed in the early stages is significantly better than that of conservative therapy (Figure 1).

The efficacy of core decompression and its limited indications are controversial topics in the literature. The choice of technique depends on the number of tunnels drilled and the diameter of the tunnels. Mont et al reported a patient series followed up for 2 years, and 71% of 45 stage I hip cases treated with a 3.2 mm multiple hole procedure had positive results.

In addition to core decompression, electrical stimulation, growth factors, bone morphogenic protein, autologous bone marrow cell concentrate, and tantalum rod implantation have been used to increase efficacy. Vascularized or nonvascularized bone grafts have also been used in combination with core decompression. Electrical stimulation has been reported to have a positive impact in patients who were treated with core decompression. Mont et al reported positive outcomes in 18 (86%) of 21 hips with allografts impregnated with bone morphogenic protein. In 2004, Liebermann et al used an autogenous fibular graft with 50 mg of bone morphogenic protein in his surgical series of 17 hip cases (15 stage IIA,
1 stage IIB, 1 stage III). They reported that 93% of hips with stage IIA disease had positive results, and that three with stage IIA, IIB, or III disease required total hip replacement. In another study, the tunnel was filled with either an autogenous iliac bone graft, an autogenous iliac bone graft ± demineralized bone matrix, or an allogenic bone graft after core decompression. Overall, positive results were reported for 65% of cases. 

Autologous concentrated bone marrow-derived mononuclear cell concentrate was first used in the treatment of osteonecrosis in the 1990s, and has been reported to have positive results. Effectiveness of bone marrow cell transfer depends on the osteogenic effect of the transplanted mononuclear cells on the femoral head. This effect is the result of angiogenic cytokines being secreted by stromal bone marrow cells injected into the femoral head and the ensuing angiogenesis. Hernigou and Beaujean have published on the results of core decompression and bone marrow cell injection in 189 cases. Only nine of 145 patients with stage I or II disease needed total hip replacement. Gangji et al used core decompression and bone marrow cell injection in 13 patients with stage I or II osteonecrosis of the femoral head, all of whom remained pain-free and did not require total hip replacement during an average follow-up period of 2 years. In their study in 2011, Gangji et al divided 24 early-stage hip cases into two groups and used either core decompression or core decompression ± bone marrow cell injection. These patients were followed up for 5 years. While eight of 11 hips in the control group progressed to the fracture stage, only three of 13 showed progression in the bone marrow group. Karapotrak et al used CD34+ cell concentrate, known to be both vasculogenic and osteogenic, in nine stage I or II hip cases following core decompression, and over a follow-up period of 27 months, there was no progression and no need for further surgical intervention in any of the cases.

Following core decompression, mesenchymal stem cells cultured on a tantalum rod were used to prevent collapse of the joint surface. In a study conducted in 2010 in China, porous tantalum rod was suggested for use in the early and intermediate stages. Floerkemeier et al compared the results of conventional core decompression and tantalum rods, and reported better results using multiple holes created with 10 mm wide drills.

Nonvascularized bone grafting
Nonvascularized bone grafting can be used to support subchondral bone and joint cartilage by removing necrotic bone tissue and replacing it with a cortical or cancellous bone graft. Three different nonvascularized grafting techniques have become popular over time. Using the Phemister technique, grafting is performed through a core decompression tract. The second method involves grafting performed through a window or a trapdoor in the femoral head. The third method is grafting through a window created at the femoral neck or femoral head-neck junction.

In the literature, core decompression and nonvascularized grafting were used in 20 stage I or II hip cases. Tibial autografting, fibular autografting, and fibular allografting were used, respectively, in three, seven, and 10 hips. Cases were followed up for a minimum of 2 years, and positive results were obtained in 17 patients. In 17 hips, the graft was placed within the lesion and adjacent to the subchondral bone. In the remaining three hips, grafts were inserted into the lesion to the level of the transitional zone between the infarct and normal bone. After performing core decompression in 85 hips with ANFH in a study in 2005, Keizer et al used...
vascularized bone grafting

Vascularized bone grafting
Following the removal of necrotic bone tissue from the femoral head, the contralateral fibula with its nutrient vessels is introduced through the head and neck of the femur, and the vessels are anastomosed microsurgically to the anterior circumflex artery and vein. Judet and Gilbert reported in 2001 that fibular grafting in stage II and III patients under 40 years of age yielded positive results in 80% of cases over a follow-up period of 18 years. However, they underlined that vascularized fibular grafting is not a good option in advanced cases. In another study, vascularized fibular grafting was used in stage II and III cases with an average follow-up of 13.9 years, with negative results and reverse total hip arthroplasty needed in 10.5% of cases. Tetik et al compared the results of vascularized and nonvascularized fibular grafting and found no significant radiological difference in outcome between the two procedures. However, the vascularized group had clinically superior results. Positive results have also been reported using vascularized pedicle iliac bone grafting combined with transtrochanteric anterior rotational osteotomy in young adults with advanced ANFH.

In 2010, Zhao et al reported the results of en bloc vascularized trochanteric grafting in 195 hip cases. The technique involved translocation of a 3 cm long and 2 cm wide graft from the anterolateral trochanter along with the transverse branch of the lateral femoral circumflex artery to the necrotic region harvested from the femoral head-neck junction in stage II–IV cases. Postoperative digital subtraction angiography performed in 46 patients showed perfusion in the graft and the femoral head in 42 cases. After an average follow-up of 8 years, total hip arthroplasty was not required in 172 patients, whereas 23 patients needed conversion to total hip arthroplasty (Figure 2).

Osteotomy

Transtrochanteric rotational osteotomy was developed by Sugioka and Yamamoto in 1978. This procedure involves transposing an intact area to a weight-bearing portion of the joint, thus resulting in transfer of a necrotic area to a non-weight-bearing portion. The clinical and radiographic prognoses after a transtrochanteric rotational osteotomy depend mainly on the ratio of the transposed intact area to the acetabular weight-bearing portion after osteotomy. The intact area transposed should be more than 36% of the weight-bearing region.

In their surgical series of 70 patients, Yamamoto et al used anterior rotational osteotomy in 57 hips with ANFH and performed rotational osteotomy in 13 hips. At the end of a 10-year follow-up period, necrotic fields had healed with osteosclerosis in 71% of cases, and the remaining cases healed with normal bone tissue. None showed progression.

In their paper published in 2008, Sugioka and Yamamoto stated that they perform posterior transtrochanteric osteotomy when the necrotic region is located in the mid and posterior sections of the femoral head. In their study following 46 stage II and III hips for a mean of 12 years, they reported a mean 52-point improvement in Harris hip score. Progression was not radiologically observed in 65% of cases, while osteoarthritic changes were found in 28%, but total hip arthroplasty was not required.

Intertrochanteric varus wedge osteotomy, commonly used in osteoarthritis, was adapted for ANFH and used in 47 patients by Ito et al, who reported positive results for Harris hip score in 74% of cases and joint space narrowing and osteoarthritic changes in 26% of cases during an average follow-up period of 18.1 years. Only six of their patients required total hip replacement or hemiarthroplasty. The average shortening was 19 mm, and the authors concluded that shortening is a problem, so curved varus osteotomy may be preferred. On the other hand, Zhao et al reported a
success rate of 83.5%, after a mean 12.3 years of follow-up in their case series of curved varus osteotomy. Good outcomes were also reported in a study where transtrochanteric rotational osteotomy and varization were used concurrently in wide lesions.

**Arthroplasty**

In patients with a large necrotic area, joint preservation is not indicated and prosthetic replacement is preferred. Hemiresurfacing, total hip resurfacing, and conventional total hip arthroplasty are contemporary arthroplasty solutions in cases of ANFH where the femoral head cannot be spared. Hemiresurfacing arthroplasty replaces only the side of the femoral head, whereas total resurfacing arthroplasty replaces the acetabular side as well. Hemiresurfacing has been referred to as “time-buying” surgery for patients with Ficat stage II and III disease. Recently, total hip resurfacing has become an alternative for both total hip arthroplasty and hemisurfacing.

Jameson et al performed resurfacing via articular surface replacement in 214 patients with ANFH who were followed up for an average of 43 months; during this time, 5.6% of patients had revision surgery and 1.9% had early femoral neck fracture. From these negative cases, they concluded that use of resurfacing in young and active patients, performing conventional total hip replacement in the rest of the patients, and use of implants with a wide-sized component option improved the success of treatment. A study reported in 2011 compared the results of hemiresurfacing and total resurfacing arthroplasty. Using need for revision surgery and pain evaluation as the criteria, total resurfacing arthroplasty was found to be superior.

In 2009, McGrath et al reported their results with primary total hip arthroplasty versus surface replacement revised with total hip arthroplasty. Their study included two groups of 39 hips each, and it was concluded that following total or hemisurface replacement, the results of revision total hip arthroplasty were equivalent to those with primary total hip arthroplasty, so surface replacement is preferable for buying time in patients with ANFH.

**Recommendations for treatment**

Core decompression should be performed either with follow-up or vascularized/nonvascularized bone grafting in asymptomatic patients with stage I or II disease. In stages IC, IIC, III, and IVA, grafting should be accompanied by core decompression, osteotomy, and arthroplasty in major lesions. Either resurfacing or total hip arthroplasty could be used in cases of Stage IVB, IVC, V, and VI disease, according to the extent of femoral head involvement.

**Conclusion**

ANFH is a progressive, multifactorial, and disabling disease commonly seen in younger adults. After collapse of the femoral head and early osteoarthritis of the hip joint, arthroplasty could be a suitable treatment option if nonoperative and joint-sparing procedures fail. Basic science research that can be used in clinical management has progressed rapidly, and these advances offer great promise for the future treatment of osteonecrosis of the hip. Clearly, ANFH is a challenging disorder to treat, but with ongoing developments in basic science and clinical investigation, more effective treatment options should become available in the future.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


39. Amstutz HC, Le Dufl M. Hip resurfacing results for osteonecrosis are as good as for other etiologies at 2 to 12 years. Clin Orthop Relat Res. 2009;467:375–381.
